PT  - JOURNAL ARTICLE
AU  - Crowley, James R.
TI  - Critical Challenges in Pluvicto Therapy: Incontinent and Anticoagulated Patients
AID  - 10.2967/jnmt.123.266482
DP  - 2023 Dec 01
TA  - Journal of Nuclear Medicine Technology
PG  - 279--281
VI  - 51
IP  - 4
4099  - http://tech.snmjournals.org/content/51/4/279.short
4100  - http://tech.snmjournals.org/content/51/4/279.full
SO  - J. Nucl. Med. Technol.2023 Dec 01; 51
AB  - As molecular therapy continues to grow, unanticipated challenges may arise, requiring the institution’s therapeutic team to reevaluate its therapeutic protocol to identify and address potential situations and challenges that may occur. This practical pointer will focus on the novel prostate cancer therapy Pluvicto (177Lu-vipivotide tetraxetan) and 2 unique situations and challenges of treating patients at the Theranostic Center at Carilion Clinic, an outpatient facility dedicated to targeted molecular therapy.